Real world data has been gaining credence among regulators for decisions on drug approval and label expansion given that randomized clinical trials take place in controlled environments in a well-defined population that might also not be truly representative of ethnic or gender diversity.
After the US Food and Drug Administration (FDA) made its first label expansion based on real world evidence in 2019...
Welcome to Scrip
Create an account to read this article
Already a subscriber?